DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluzone Quadrivalent vaccine, 2018-2019 formulation
Biological: Flublok Quadrivalent vaccine, 2018-2019 formulation
Biological: Fluzone High-Dose vaccine, 2018-2019 formulation

First Posted Date: 2018-08-06

Last Posted Date: 2022-03-29

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 240

Registration Number: NCT03617523

Locations: 🇺🇸
Investigational Site Number 8400001, Metairie, Louisiana, United States
🇺🇸
Investigational Site Number 8400003, Bardstown, Kentucky, United States
🇺🇸
Investigational Site Number 8400002, Salt Lake City, Utah, United States

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Phase 3

Completed

Conditions: Meningococcal Infections

Interventions: Biological: MenACYW conjugate vaccine
Biological: Meningococcal group A, C, W-135, and Y conjugate vaccine
Biological: DTaP-IPV-HB-Hib vaccine
Biological: Pneumococcal vaccine (10-valent)
Biological: Pneumococcal vaccine (13-valent)
Biological: MMR vaccine

First Posted Date: 2018-06-06

Last Posted Date: 2025-03-03

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1660

Registration Number: NCT03547271

Locations: 🇨🇿
Investigational Site Number : 2031006, Chlumec Nad Cidlinou, Czechia
🇨🇿
Investigational Site Number : 2031013, Domazlice, Czechia
🇨🇿
Investigational Site Number : 2031010, Jindrichuv Hradec, Czechia

and more 30 locations

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluzone Quadrivalent Influenza Vaccine

First Posted Date: 2018-06-06

Last Posted Date: 2022-03-29

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 120

Registration Number: NCT03546192

Locations: 🇵🇭
Sanofi Pasteur Investigational Site 002, Manila, Philippines
🇵🇭
Sanofi Pasteur Investigational Site 003, Manila, Philippines
🇵🇭
Sanofi Pasteur Investigational Site 001, Quezon City, Philippines

Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea

Completed

Conditions: Yellow Fever

First Posted Date: 2018-05-30

Last Posted Date: 2019-03-26

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 622

Registration Number: NCT03541694

Locations: 🇰🇷
Sanofi Pasteur Investigational Site 001, Seoul, Korea, Republic of

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Phase 3

Completed

Conditions: Healthy Volunteers (Meningococcal Infection)

Interventions: Biological: MenACYW conjugate vaccine
Biological: MenACYW-135 conjugate vaccine
Biological: DTaP-IPV//Hib vaccine
Biological: Pneumococcal 13-valent conjugate vaccine
Biological: Pentavalent rotavirus vaccine
Biological: Hepatitis B vaccine
Biological: Measles, mumps, rubella (MMR) vaccine
Biological: Varicella vaccine
Biological: Hepatitis A vaccine

First Posted Date: 2018-05-25

Last Posted Date: 2024-10-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2627

Registration Number: NCT03537508

Locations: 🇺🇸
Helios Clinical Research Site Number : 8400109, Houston, Texas, United States
🇺🇸
Wee Care Pediatrics Syracuse Site Number : 8400024, Syracuse, Utah, United States
🇺🇸
Birmingham Pediatric Associates Site Number : 8400026, Birmingham, Alabama, United States

and more 67 locations

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Phase 3

Completed

Conditions: Meningococcal Infections

Interventions: Biological: MenACYW conjugate vaccine

First Posted Date: 2018-03-23

Last Posted Date: 2022-04-06

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 91

Registration Number: NCT03476135

Locations: 🇫🇮
Sanofi Pasteur Investigational Site 2460005, Espoo, Finland
🇫🇮
Sanofi Pasteur Investigational Site 2460006, Helsinki, Finland
🇫🇮
Sanofi Pasteur Investigational Site 2460003, Tampere, Finland

and more 5 locations

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

Phase 1

Completed

Conditions: Influenza
Flu

Interventions: Biological: Shz QIV 0.5 mL, single dose
Biological: Shz QIV 0.25 mL, 2 doses
Biological: Shz QIV 0.5 mL, 2 doses

First Posted Date: 2018-02-12

Last Posted Date: 2022-11-09

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 101

Registration Number: NCT03430089

Locations: 🇨🇳
Investigational Site 002, Xishuangbanna, Yunnan, China

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Multi-dose Quadrivalent Influenza Vaccine
Biological: Single-dose Quadrivalent Influenza Vaccine

First Posted Date: 2018-01-05

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 301

Registration Number: NCT03391193

Locations: 🇲🇽
Sanofi Pasteur Investigational Site 0002, Ecatepec de Morelos, Estado De Mexico, Mexico
🇲🇽
Sanofi Pasteur Investigational Site 0001, Cuernavaca, Morelos, Mexico
🇲🇽
Sanofi Pasteur Investigational Site 0003, Mexico City, Mexico

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Phase 4

Completed

Conditions: Flu
Influenza

Interventions: Biological: Fluzone Quadrivalent vaccine
Biological: Fluzone High-Dose vaccine

First Posted Date: 2017-10-13

Last Posted Date: 2022-03-29

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 240

Registration Number: NCT03308825

Locations: 🇺🇸
Sanofi Pasteur Investigational Site 002, Bardstown, Kentucky, United States
🇺🇸
Sanofi Pasteur Investigational Site 001, Metairie, Louisiana, United States
🇺🇸
Sanofi Pasteur Investigational Site 003, Council Bluffs, Iowa, United States

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: QIV-HD
Biological: Licensed TIV-HD1
Biological: Investigational TIV-HD2

First Posted Date: 2017-09-13

Last Posted Date: 2022-04-07

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2670

Registration Number: NCT03282240

Locations: 🇺🇸
Sanofi Pasteur Investigational Site 003, San Diego, California, United States
🇺🇸
Sanofi Pasteur Investigational Site 010, Boise, Idaho, United States
🇺🇸
Sanofi Pasteur Investigational Site 029, Redding, California, United States

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy